Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LM-108 |
Trade Name | |
Synonyms | LM 108|LM108 |
Drug Descriptions |
LM-108 is a monoclonal antibody that targets CCR8 expressed on regulatory T cells and inhibits downstream signaling, potentially leading to increased antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2504), NCI Drug Dictionary). |
DrugClasses | CCR8 Antibody 9 |
CAS Registry Number | NA |
NCIT ID | C186374 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
LM-108 | LM-108 | 0 | 2 |
LM-108 + Pembrolizumab | LM-108 Pembrolizumab | 0 | 0 |
LM-108 + Toripalimab-tpzi | LM-108 Toripalimab-tpzi | 0 | 0 |
LM-108 + unspecified PD-1 antibody | LM-108 unspecified PD-1 antibody | 0 | 2 |